New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
18:40 EDTRMBS, APA, HLX, NFLX, TEP, TGTX, CYS, CMG, UCTT, JNJ, CNI, SANMOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
News For NFLX;SANM;CMG;HLX;CNI;CYS;APA;JNJ;TGTX;RMBS;UCTT;TEP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
June 19, 2015
14:07 EDTNFLXOptions with increasing implied volatility: NFLX CI TRIP AET
09:37 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:18 EDTTGTXOn The Fly: Pre-market Movers
Subscribe for More Information
07:30 EDTNFLXNetflix price target raised to $800 from $610 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his 12-18 month price target for shares of Netflix to $800 from $610. The streaming service closed yesterday up $3.30 to $663.20. The new target reflects the company's plans to enter Japan, Cuba, Spain, Italy and Portugal, all in 2015, the analyst tells investors this morning in a research note. Helfstein's revised model assumes global subscribers of 239M in 2020, equaling 32% penetration of broadband homes, which the analyst says is consistent with Netflix's 2015 rates in older markets. He reiterates an Outperform rating on the stock.
05:47 EDTCMGStocks with implied volatility movement; MYLCMG
Subscribe for More Information
June 18, 2015
16:49 EDTRMBSRambus, SK Hynix extend license agreement
Subscribe for More Information
12:10 EDTSANMContract electronic manufacturers underperform after Jabil results
Subscribe for More Information
11:31 EDTNFLXOptions with increasing implied volatility
Subscribe for More Information
11:17 EDTTGTXTG Therapeutics announces Phase 2 clinical trial results of TG-1101
TG Therapeutics announced updated clinical results from its Phase 2 study of TG-1101, the company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, the oral BTK inhibitor. TG-1101 in combination with ibrutinib was well tolerated in the 44 CLL patients evaluable for safety, with day 1 infusion related reactions being the most frequently reported adverse event, the majority of which were Grade 1 or 2 in severity. Only 3 Grade 3 or 4 adverse events were observed in > 5% of patients: neutropenia, anemia, and IRR. Adverse events were manageable with only 7% of CLL patients discontinuing from the study due to an adverse event: 1 diarrhea and 2 non-related adverse events. Overall, aside from day 1 IRR, the addition of TG-1101 to ibrutinib did not appear to alter the safety and tolerability profile of ibrutinib monotherapy. Of the 44 CLL patients treated, 40 were evaluable for response. The 4 patients who were not evaluable included 2 who discontinued due to an adverse event and 2 who withdrew consent, in each case, prior to a first efficacy assessment. Of the 20 CLL patients with previously treated high-risk disease, the patient population we are currently studying in our Phase 3 GENUINE study, 95% achieved an objective response with 20% achieving MRD negativity and/or a CR or an unconfirmed CR (pending bone marrow confirmation) as per the iwCLL. Additionally, disease response improved for the high-risk CLL patients from a median 64% nodal reduction by month 3 to a median 85% nodal reduction by month 6. Amongst all 40 CLL patients evaluable for efficacy, 88% (35/40) achieved an objective response per the iwCLL criteria and 4 patients, or an additional 10%, achieved nodal reductions ranging from 20%-55%, without disease progression.
June 17, 2015
17:18 EDTNFLXSpotify hires ex-Netflix CFO Barry McCarthy as company CFO, WSJ says
Subscribe for More Information
16:56 EDTNFLXSpotify hires ex-Netflix CFO Barry McCarthy as company CFO, Dow Jones says
15:36 EDTCNICanadian National signs memorandum of understanding with Port of New Orleans
Canadian National signed a memorandum of understanding with the Port of New Orleans that will see the parties develop additional supply chain efficiencies aimed at drawing more container traffic over the port to North American markets. JJ Ruest, Canadian's EVP and Chief Marketing Officer, said, "We and our Port of New Orleans gateway partners have a mutual interest in ensuring a more competitive rail movement of containerized goods through the gateway and into the Midwest and mid-continent... The expanded Panama Canal is expected to offer greater freight traffic opportunities to the ports of New Orleans and Mobile. Our plan to implement level-of-service agreements at these two ports and raise their involvement in rail transportation should help them take advantage of rising container trade with Asia and South America." The Port of New Orleans has an intermodal rail terminal adjacent to its Napoleon Avenue Container Terminal providing on-dock access for all rail shipments. The new Mississippi River Intermodal Terminal is currently under construction. The $25M project, planned for completion in 1Q16, will result in a more efficient container transfer terminal located within the container yard, offering on-dock access and improving Canadian's link to the terminal and helping grow its container volumes, as claimed by the company.
11:08 EDTNFLXOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTCYSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:40 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:36 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL FB AMD ADBE TWTR BABA QIHU NFLX BAC
08:15 EDTCYSCYS Investments downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded CYS Investments to Underperform from Neutral and lowered its price target to $7.50 from $8.50. The firm said the operating backdrop for mREITs remains challenging and is increasingly concerned higher rates, widening spreads, and increased volatility will pressure shares. BofA/Merrill expects a flatter yield curve to reduce earnings power long-term, ultimately leading to potential dividend cuts.
07:21 EDTJNJGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
07:17 EDTTGTXOncology Institute of Southern Switzerland to hold a conference
13th International Conference on Malignant Lymphoma: ICML 2015 is being held in Rome, Italy on June 17-20.
06:20 EDTNFLXHulu luring content producers from Netflix, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use